What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

STATEMENT OF NEED

In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan receiving approval as the first targeted therapy for pretreated, HER2-mutated, advanced NSCLC (Ren et al, 2022; Ferrari et al, 2024). As HER2-directed therapies for NSCLC enter the clinic, it is crucial that clinicians remain up to date on the implications of HER2 alterations on treatment planning and their role in evidence-based management. In Module 2 of this activity, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, will explore actionable insights and testing recommendations for HER2 alterations in NSCLC.

TARGET AUDIENCE

Oncologists, pulmonologists, oncology nurses, advanced practice providers, and other health care professionals involved in the treatment of patients with non"small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

Discuss the significance of HER2 mutations in NSCLC and their implications for treatment planning
Assess current and emerging treatment strategies for HER2-mutated NSCLC and their role in evidence-based management